Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research
“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected by the disease,” reports the National Cancer Institute. CLDI is reporting preclinical results for its systemic RTNova platform, which has successfully delivered transient gene therapy payloads to targeted tumors. “With this breakthrough, we can use our platform to develop multiple assets for various indications,” says CEO. Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE…